This product page is intended for qualified business, laboratory, or research-related inquiry. Availability and permitted use depend on destination country and local regulations.
Confirm product name, preferred specification, quantity, and packaging requirement before quotation.
Ask for available specification sheet, packaging details, or product-related quality documentation.
Use Inquiry Cart or the quote form so our team can reply with availability, lead time, and shipping communication.
B7-33 is a novel, synthetic compound that was first discovered and developed by a team of researchers at the Monash University in Australia. The development of B7-33 was based on the discovery of the relaxin receptor 1 (RXFP1) and the recognition of its potential as a therapeutic target for a wide range of diseases and conditions.
The research team, led by Professor David Handelsman, first synthesized B7-33 in the early 2010s as part of their efforts to develop a functionally selective agonist for RXFP1. This compound was then tested in a series of in vitro and in vivo studies, which demonstrated its potential as a treatment for hypertension, kidney disease, and heart failure. The team's research on B7-33 was published in several scientific journals, including the Journal of Biological Chemistry and the Journal of Hypertension.
These publications highlighted the compound's unique mechanism of action and its potential as a treatment option for patients.
Request a Quote
Send your quantity, destination country, and preferred contact method. Our team will reply with availability and quotation details.